Latest From ResMed Inc.
ResMed expects to pay more than $40m to settle a Department of Justice investigation into the company’s resupply program.
A new multinational analysis by ResMed showed that the number of people with sleep apnea is 10 times higher than previous estimates by the World Health Organization, raising the need for developing strategies to raise awareness of the disease and diagnose and treat the disease.
The relative absence of blockbuster M&A within medtech in 2018, compared with recent years, does not mean that consolidation of the industry – and of providers and payers – will not continue apace in 2019 and beyond. In fact, it is written – if not in the stars then possibly in digital coding – that there will be fewer and bigger entities at the top end of the ecosystem of medtech stakeholders. And rising demand will be met more and more by digital tools and functionalities.
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
- Therapeutic Areas
- Neurology, Nervous System
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- ResMed Inc.
- Senior Management
Michael Farrell, CEO
Robert Douglas, Pres. & COO
- Contact Info
Phone: (858) 836-5000
9001 Spectrum Ctr. Blvd.
San Diego, CA 92123
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.